Physician profile
David S Koslov
NPI 1043655525
$5,002.26
in general payments reported to CMS, 2019-2025
25 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $174 · 2021: $1,345 · 2022: $677 · 2023: $809 · 2024: $1,136 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.61 |
| Education | $135.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,007.57 | 2021-2023 | Titan, Speedicath, Restorelle |
| Abbvie INC. | $690.33 | 2020-2025 | |
| Caldera Medical, INC | $508.06 | 2024 | Desara |
| Astellas Pharma US INC | $446.49 | 2021-2025 | Xtandi, Myrbetriq |
| Biotissue Holdings INC. | $257.92 | 2021-2024 | |
| Boston Scientific Corporation | $244.29 | 2020-2024 | Ams 700 Cxr Rte Kit, Upsylon, Solyx Sis System |
| Myovant Sciences INC. | $237.66 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.45 | 2020-2025 | |
| Galt Medical | $218.93 | 2019 | |
| Janssen Biotech, INC. | $181.49 | 2024-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $177.81 | 2020-2025 | |
| Tolmar, INC. | $172.13 | 2023-2025 | Eligard |
| Sumitomo Pharma America, INC. | $121.60 | 2023-2025 | Orgovyx |
| Teleflex LLC | $118.23 | 2021-2022 | |
| Urogen Pharma, INC. | $70.68 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $50.00 | 2023 | Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $48.86 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $47.26 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $33.20 | 2020-2021 | |
| Mimedx Group, INC. | $25.49 | 2025 | |
| Urovant Sciences INC | $24.96 | 2022 | |
| Axonics, INC. | $19.81 | 2024 | Axonics |
| Tolmar Pharmaceuticals, INC. | $18.82 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Koslov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.